Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

26/02/2015 - 2 minutes

Ferring Pharmaceuticals signed an agreement with South Korean CTCBIO to acquire rights to a novel oral drug delivery technology. The Swiss company is growing more and more rapidly with plenty of updates since the begining of the year.

Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin (MINIRIN) and the fast dissolving lyophilisate (MINIRIN MELT), is well known. Its portfolio of peptide therapeutics makes them an attractive partner for specialised technology-based companies like CTCBIO. Based in Seul, CTCBIO is a growing specialised company that has developed successful manufacturing technologies for more than 30 different drugs, including treatments for dementia and asthma.

Dr. Jeon, Hongryeol, Vice President of CTCBIO, explained: “Keeping the active pharmaceutical ingredient stable and secure is critical. This technology makes this possible and is particularly useful for hydrophilic macromolecules like peptides and proteins while offering the advantage of oral administration.

The Swiss pharma has been a pioneer in the development of novel oral drug delivery technologies.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!